Cochlioquinone A, isolated from the fungus Helminthosporium sativum, was found to have nematocidal activity. Cochlioquinone A is a competitive inhibitor of specific [3H] ivermectin binding suggesting that cochlioquinone Aand ivermectin interact with the same membranereceptor.
[3H]Ivermectin was labeled at the 22,23-position by catalytic hydrogenation with tritium gas to a specific activity of S1.9 Ci/mmol. Purity of [3H]ivermectin was confirmed using TLC on Silica gel 60-F 254 (E.M. Laboratories, Inc. ). The plate was developed with chloroform -ethyl acetate -methanol -methylene chloride (9 :9 : 1 :2). The Rfvalue was 0.51, and the [3H]ivermectin was found to be greater than 95% pure. Corn steep liquor was obtained from Sigma Chem. Corp. (St. Louis, MO.); tomato paste was from Hunt's; oat flour was purchased from a retail grocery store; NZ-AmineA was from Sheffield and all other compounds were obtained from commercial sources. sterilization. The mediumwas dispensed at 25O-ml/5OO-ml Erlenmeyer flask; cotton closures were used. It was sterilized at 121°C for 15 minutes. Seed cultures ofH. sativum were inoculated with a source of the culture (three 5 mmagar plugs from a well-sporulated potato -glucose agar plate) and grown on a gyratory shaker (220 rpm; 5. 1-cm throw) for 48 hours at 25°C. The culture grew as a mycelial mass. In order to break up the mass and facilitate inoculation of the production medium, approximately 20 small, sterile, ceramic balls were added to the seed flask and it was incubated on a gyratory shaker for 20 minutes.
Fermentation Conditions
A portion of the seed culture (12 ml) was used to inoculate each flask containing 250ml of the liquid production medium. The inoculated mediumwas added to a 2-liter Erlenmeyer flask which contained vermiculite (70g; sterilized for 1 hour at 121°C). The mixture was shaken vigorously by hand to coat the vermiculite with the medium. Production flasks were incubated statically at 25°C for 14 days.
Isolation and Identification of Cochlioquinone A Bioassay-directed fractionation of a methylethylketone extract of the fermentation broth of H. sativum proceeded via solvent partitioning (activity was soluble in methylene chloride) followed by two successive silica gel columnchromatographic steps with methylene chloride -ethyl acetate gradients. Final purification was achieved by semi-preparative HPLCon a Rainin Dynamax60A C18 column (2.5 cm x 25 cm) eluted at 10 ml/minute with 50%aqueous acetonitrile. The biactive material, whose homogeneity was verified by TLC in several solvent systems and by HPLC(Whatman Partisil-5 ODS-3, 55 % aqueous acetonitrile) was readily identified as the known fungal metabolite cochlioquinone A, by comparison of spectroscopic data (UV, NMRand MS) with published values.3) Someinstability of the bioactivity was noted during the course of purification; this was ultimately traced to the sensitivity of cochlioquinone A to light, which is particularly pronounced in methanolic solutions.
Motility Assay
Wormswere rinsed off the agar plates with room temperature 5 mMTrizma base, adjusted to pH 7.5 with HC1, washed two times by centrifugation at 1,000x^for 2 minutes and then resuspended in the 5-mMTris buffer. Aliquots of the worms (50//1, approximately 100 worms) were placed into 13 x 100mm glass test tubes. The compoundsto be tested were added to the wormsin a final volume of 500{Aof the Tris buffer containing 1 %dimethyl sulfoxide. After 16 hours incubation at 22°C, the number of wormsstill motile was determined by examination with a low power dissecting microscope. Greater than 90%of the wormscontinued to swimvigorously in the control tube.
MembranePreparation
C. elegans, N2strain was cultivated on NGagar plates covered with a lawn of Escherichia coli as previously described.4) Worms(all stages) were washed off the plates with the 5-mMTris buffer. The worms were centrifuged 2 minutes at 1,000 x g, resuspended in buffer (approximately 20,000 worms/ml) and then broken up by homogenization in a Braun Homogenizer (Ace Scientific, New Brunswick, NJ.) using 0.5 mm glass beads for 20 seconds. The homogenate was centrifuged 2 minutes at 1,000 x g and the supernatant centrifuged 20 minutes at 28,000 x g. The resulting pellet was resuspended in buffer and washedthree more times by centrifugation at 28,000 x g for 20 minutes in order to dilute cytoplasmic contaminants as well as possible. The final pellet was resuspended in Tris buffer and used immediately.
Ivermectin Binding Assay
The membrane preparations ( 1.0 ml in 13 x 100 mmglass tubes) were incubated with [3H]ivermectin at 22°C for 45 minutes in the presence (nonspecific binding) or absence (total binding) of a 500-fold molar excess of unlabeled ivermectin. The incubation was terminated by rapid filtration over WhatmanGF/B filters (pretreated with 0. 15%polyethylimine and 0.25% Triton X-100 in order to minimize nonspecific binding) and rinsed with 15ml (3 x 5ml) of ice-cold HEPES buffer containing 0.5% Triton X-100. The filters were placed into glass vials containing 10ml Aquasol II (New England Nuclear, Boston, MS), and radioactivity was determined by liquid scintillation spectometry at 62% efficiency. Specific binding was calculated by subtracting nonspecific total binding.
Protein Assays
Protein concentrations were determined using the dye staining technique of Bradford.5)
Results
Cochlioquinone A Effect on C. elegans Motility C. elegans was incubated in the presence of increasing concentrations of cochlioquinone A and the percentage of motile worms quantitated after 16 hours. The ED50 (the concentration at which 50% of the worms remain motile) for cochlioquinone A was 135 //M (Fig. 2) . Ivermectin-resistant mutants of C. elegans were also less sensitive to cochlioquinone A, with an ED50 of greater than 1 mM.In parallel experiments, the . SEPT. 1990 EDso values for ivermectin using wild type and ivermectin resistant C. elegans were 5 and 75nM, respectively.
Cochlioquinone Inhibition of Ivermectin Binding In order to determine whether cochlioquinone A is interacting directly with the ivermectin binding site, C. elegans membranes were incubated with increasing concentrations of [3H]ivermectin in the presence or absence of a fixed concentration of cochlioquinone A (45 and 90 //M). The double reciprocal plot of these data (Fig. 3) Other anthelmintic agents (cambendazole, phenothiazine, levamisole and paraherquamide) were tested and none inhibited ivermectin binding at concentrations up to 1 mM(data not shown).
Discussion
The mode of action of ivermectin (and all of the biologically active avermectin analogs) is thought to be mediated via a specific receptor site regulating a non-GABA gated chloride ion channel.6'7* In invertebrate neuromuscular preparations, subnanomolar concentrations of ivermectin significantly increase the membrane permeability to chloride ions. We have previously identified and characterized a specific ivermectin binding site in a membrane fraction prepared from the free living nematode C. elegans.
2) The results presented in this study demonstrate that cochlioquinone Ais a competitive inhibitor of ivermectin binding with an inhibition constant, Ki, of 30jjm. In addition, cochlioquinone A has nematocidal activity as determined in a motility assay (ED50-135jUM). Although there is no obvious structural similarity between cochlioquinone A and the avermectins, the inability of cochlioquinone A to immotilize the ivermectinresistant C. elegans mutants further supports the hypothesis that cochlioquinone Aand ivermectin are acting at the same binding site. Weare currently studying the effect of cochlioquinone on ivermectin-sensititive chloride channels. This is the first report of a non-avermectin interacting with an invertebrate avermectin binding site, and although the affinity of cochlioquinone A for the ivermectin binding site is relatively low, cochlioquinone Amay provide a useful tool for studying the anthelmintic activity of the avermectins.
